HOPE We have what we need to fight both H5N1 and H

Message Topic Search Topic Options Post Reply Create New Topic Printable Version Translate Topic

Hi Gang, I have not been on since last April or May and can not remember my password.  I recalled that during the H5 scare there were a couple new meds in the loop.  I did some google research and I was  correct. I will attempt to paste a small article here but it case it fails check yourselves by searching two things the first CS-8958 goes by the name Laninamivir Octinate it is a anti-viral and a new one specifically for H5N1 very effective being produced in Japan by Daichi Sankyo Co. ltd. also another new anti-viral that works against both H5N1 and H7N9 and many more because it targets a different part of the virus then former anti virals did, this one is T705 it enables the human T fighter cells to be more effective in attacking the part of flu virus that ALL flu virus share, their common genetic parts that all virus share, making it so that when the virus mutates the drug will still work because of its ability to effect the common genetic properties.  
This came out five years ago, this is NOT new. The emergence of H5N1 is what spurred the research community on. There are pages and pages of info on both these meds if you google them. T705 goes by the name Faviravir also produced in Japan and several places in the USA Texas being one of the places and Nutritional Biochem in Cleveland Ohio being another. 
Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
 http://www.ncbi.nlm.nih.gov/pubmed?term=Furuta%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Furuta Y,  http://www.ncbi.nlm.nih.gov/pubmed?term=Gowen%20BB%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Gowen BB,  http://www.ncbi.nlm.nih.gov/pubmed?term=Takahashi%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Takahashi K,  http://www.ncbi.nlm.nih.gov/pubmed?term=Shiraki%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Shiraki K,  http://www.ncbi.nlm.nih.gov/pubmed?term=Smee%20DF%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Smee DF,  http://www.ncbi.nlm.nih.gov/pubmed?term=Barnard%20DL%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Barnard DL.
 http://www.ncbi.nlm.nih.gov/pubmed/24084488# - Author information  
Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama 930-8508, Japan. Electronic address: yousuke_furuta@toyama-chemical.co.jp.
Abstract
Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (RTP). Its antiviral effect is attenuated by the addition of purine nucleic acids, indicating the viral RNA polymerase mistakenly recognizes favipiravir-RTP as a purine nucleotide. Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options. A Phase III clinical evaluation of favipiravir for influenza therapy has been completed in Japan and two Phase II studies have been completed in the United States. In addition to its anti-influenza activity, favipiravir blocks the replication of many other RNA viruses, including arenaviruses (Junin, Machupo and Pichinde); phleboviruses (Rift Valley fever, sandfly fever and Punta Toro); hantaviruses (Maporal, Dobrava, and Prospect Hill); flaviviruses (yellow fever and West Nile); enteroviruses (polio- and rhinoviruses); an alphavirus, Western equine encephalitis virus; a paramyxovirus, respiratory syncytial virus; and noroviruses. With its unique mechanism of action and broad range of antiviral activity, favipiravir is a promising drug candidate for influenza and many other RNA viral diseases for which there are no approved therapies. 
Copyright © 2013 Elsevier B.V. All rights reserved.

Author	Message Topic Search Topic Options Post Reply Create New Topic Printable Version Translate Topic
Debbie NC Members Profile Send Private Message Find Members Posts Add to Buddy List Guest Group	Post Options Post Reply Quote Debbie NC Thanks(0) Quote Reply Topic: HOPE We have what we need to fight both H5N1 and H Posted: January 14 2014 at 9:21pm
	Hi Gang, I have not been on since last April or May and can not remember my password. I recalled that during the H5 scare there were a couple new meds in the loop. I did some google research and I was correct. I will attempt to paste a small article here but it case it fails check yourselves by searching two things the first CS-8958 goes by the name Laninamivir Octinate it is a anti-viral and a new one specifically for H5N1 very effective being produced in Japan by Daichi Sankyo Co. ltd. also another new anti-viral that works against both H5N1 and H7N9 and many more because it targets a different part of the virus then former anti virals did, this one is T705 it enables the human T fighter cells to be more effective in attacking the part of flu virus that ALL flu virus share, their common genetic parts that all virus share, making it so that when the virus mutates the drug will still work because of its ability to effect the common genetic properties. This came out five years ago, this is NOT new. The emergence of H5N1 is what spurred the research community on. There are pages and pages of info on both these meds if you google them. T705 goes by the name Faviravir also produced in Japan and several places in the USA Texas being one of the places and Nutritional Biochem in Cleveland Ohio being another. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. http://www.ncbi.nlm.nih.gov/pubmed?term=Furuta%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Furuta Y, http://www.ncbi.nlm.nih.gov/pubmed?term=Gowen%20BB%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Gowen BB, http://www.ncbi.nlm.nih.gov/pubmed?term=Takahashi%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Takahashi K, http://www.ncbi.nlm.nih.gov/pubmed?term=Shiraki%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Shiraki K, http://www.ncbi.nlm.nih.gov/pubmed?term=Smee%20DF%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Smee DF, http://www.ncbi.nlm.nih.gov/pubmed?term=Barnard%20DL%5BAuthor%5D&cauthor=true&cauthor_uid=24084488 - Barnard DL. http://www.ncbi.nlm.nih.gov/pubmed/24084488# - Author information Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama 930-8508, Japan. Electronic address: yousuke_furuta@toyama-chemical.co.jp. Abstract Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (RTP). Its antiviral effect is attenuated by the addition of purine nucleic acids, indicating the viral RNA polymerase mistakenly recognizes favipiravir-RTP as a purine nucleotide. Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options. A Phase III clinical evaluation of favipiravir for influenza therapy has been completed in Japan and two Phase II studies have been completed in the United States. In addition to its anti-influenza activity, favipiravir blocks the replication of many other RNA viruses, including arenaviruses (Junin, Machupo and Pichinde); phleboviruses (Rift Valley fever, sandfly fever and Punta Toro); hantaviruses (Maporal, Dobrava, and Prospect Hill); flaviviruses (yellow fever and West Nile); enteroviruses (polio- and rhinoviruses); an alphavirus, Western equine encephalitis virus; a paramyxovirus, respiratory syncytial virus; and noroviruses. With its unique mechanism of action and broad range of antiviral activity, favipiravir is a promising drug candidate for influenza and many other RNA viral diseases for which there are no approved therapies. Copyright © 2013 Elsevier B.V. All rights reserved.

cobber Members Profile Send Private Message Find Members Posts Add to Buddy List Guest Group	Post Options Post Reply Quote cobber Thanks(0) Quote Reply Posted: January 14 2014 at 10:03pm
	The big hope coming out of the US is a drug called fluicide. It created by a company called Nanoviricides (NNVC). Its still in early stages, and needs to go thru full FDA approval yet. They have achieved remarkable results so far and if it works as they predict will become the new wonder drug. Something akin to the impact penicillin had.